Biotechnology News and Research

RSS

Nuron Biotech announces acquisition of Wyeth's HibTITER vaccine assets

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has acquired assets relating to the vaccine HibTITER from Wyeth LLC, a wholly owned subsidiary of Pfizer Inc, for the U.S. and many other markets, including Japan and Korea. Financial terms of the sale were not disclosed.

7 Apr 2011

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced that it has successfully completed two Phase 1a clinical studies for AVL-292, its orally-available, selective inhibitor of Bruton's tyrosine kinase (Btk).

6 Apr 2011

Ascletis raises $100 million in committed financing

Ascletis, Inc., a U.S.-China specialty life sciences venture focused on cancer and infectious disease therapeutics, today announced the company's formation and completion of a Series A private equity financing. Ascletis has raised US$100 million in committed financing including a first tranche of US$50 million. The investors, led by Hangzhou Binjiang Investment Holding Co., Ltd., included private entrepreneurs from China and other countries including the United States.

6 Apr 2011

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Circadian Technologies announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.

6 Apr 2011

Record number of medicines for various cancers in clinical trials

A record 887 medicines for various of cancers are in clinical trials or awaiting Food and Drug Administration (FDA) review—well over double the number in the pipeline just six years ago, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

6 Apr 2011

Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today presented results of preclinical studies on its novel Phosphoinositide 3-kinase alpha inhibitor at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

6 Apr 2011

U.S. biotech company chooses OmniComm's SaaS model for 4 clinical studies

OmniComm Systems, Inc., one of the fastest growing companies in the EDC marketplace, today announced that its TrialMaster suite of applications and IVRS technology has been chosen by a prominent biotechnology company to manage their clinical data management and randomization needs for 4 key clinical trials.

6 Apr 2011

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme Corp., a subsidiary of sanofi-aventis Group, and Isis Pharmaceuticals Inc. announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

6 Apr 2011

OSU chemist developing solution to nerve agent exposure

Scientists are working to develop a new drug that will regenerate a critical enzyme in the human body that “ages” after a person is exposed to deadly chemical warfare agents.

5 Apr 2011

VisualSonics demonstrates Vevo LAZR imaging system at AACR conference

VisualSonics Inc., a leader in real time, in vivo, high-resolution micro-imaging systems and a wholly-owned subsidiary of SonoSite Inc., is demonstrating the recently announced Vevo LAZR Photoacoustics Imaging system at the American Association of Cancer Research's annual conference.

5 Apr 2011

Morphotek acquires tumor targeting assets from TMI

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has acquired certain assets relating to a proprietary tumor targeting platform from TransMolecular, Inc. for an undisclosed upfront payment and future development milestones.

4 Apr 2011

Sigma-Aldrich establishes European Regional Headquarters in Switzerland

Sigma-Aldrich Corporation opened its European Regional Headquarters today in St. Gallen, Switzerland. The new Einstein Facility located in the heart of St. Gallen will be home to approximately 50 employees.

4 Apr 2011

Axxora.com to distribute TGR's new ELISAONE technology assay reagents in the US and South America

TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Axxora.com of San Diego, CA, US, a leading online global market place resource for innovative and high quality Life Science research reagents.

4 Apr 2011

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload technology, today disclosed the profile and first preclinical data for the Company's novel IMGN529 product candidate for the treatment of B-cell malignancies including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

4 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.

4 Apr 2011

Miltenyi Biotec launches MACSQuant VYB benchtop flow cytometer

Miltenyi Biotec today announces the worldwide release and availability of the MACSQuant VYB, a compact, benchtop flow cytometer featuring violet, yellow, and blue lasers, and detection of 10 optical parameters.

4 Apr 2011

Techne's R&D Systems acquires Boston Biochem assets

Techne Corporation announced today that as of April 1, 2011, its R&D Systems subsidiary has acquired the assets of Boston Biochem, Inc., a leading developer and manufacturer of innovative ubiquitin-related research products.

4 Apr 2011

Sanofi-aventis completes exchange offer for all shares of Genzyme common stock

Sanofi-aventis announced today that it has successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.

4 Apr 2011

Life Technologies launches new TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the launch of its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools with the precision to detect a single mutant molecule hiding in a background of 1 million normal copies.

4 Apr 2011